Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 1997

View Archived Issues

Nippon Kayaku reports neuritogenic effects for known compound

Natural compounds that inhibit oncogene function from Terumo

Japan Tobacco discloses cytokine inhibitors

Antioxidants reported by Hoechst Marion Roussel

Genzyme Transgenics: Q1 1997 highlights

Pfizer seeks to become premier healthcare company in world, CEO tells shareholders

Inhale Therapeutic Systems: Q1 1997 highlights

Genzyme General: Q1 1997 highlights

Positive clinical results for pramipexole in schizophrenia

SmithKline Beecham launches antiviral cream for treatment of cold sores

Clodronate shows comparable efficacy to indomethacin in a rat model of arthritis

Modafinil for sleep apnea-hypopnea syndrome

Targeted Genetics' E1A tumor suppressor gene product progresses in clinical trials

Company Profile: XTL Biopharmaceuticals

Company Profile: Epix Medical

Ethical initiates U.S. pivotal trials of HRT combination patch

FDA clears Hemagen's RF test

Zeneca and the University of Oxford enter collaboration for genetic research into heart disease

Oxford BioMedica acquires anticancer macrophage technology

Agouron acquires Alanex

Neurobiological Technologies initiates second phase II memantine trial

Cortech and Ono amend research agreement

Sheffield Medical Technologies acquires Camelot Pharmacal

Somatogen initiates phase II Optro trial for new indication

Oncor licenses new genetic biomarker for prostate cancer

Nanogen granted U.S. patent on APEX technology

CoCensys and Novartis end stroke compound collaboration

Alpharma's Oral Acyclovir Suspension launched in the U.S.

Abbott to acquire certain Sanofi businesses

Biomatrix's viscosupplementation product to be distributed by Bayer

OXiGENE initiates U.S. preclinical and clinical research

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026